521 related articles for article (PubMed ID: 20060421)
21. In vitro inhibition of dengue virus entry by p-sulfoxy-cinnamic acid and structurally related combinatorial chemistries.
Rees CR; Costin JM; Fink RC; McMichael M; Fontaine KA; Isern S; Michael SF
Antiviral Res; 2008 Nov; 80(2):135-42. PubMed ID: 18606464
[TBL] [Abstract][Full Text] [Related]
22. Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2'-ethynyl-7-deaza-adenosine triphosphate.
Latour DR; Jekle A; Javanbakht H; Henningsen R; Gee P; Lee I; Tran P; Ren S; Kutach AK; Harris SF; Wang SM; Lok SJ; Shaw D; Li J; Heilek G; Klumpp K; Swinney DC; Deval J
Antiviral Res; 2010 Aug; 87(2):213-22. PubMed ID: 20470829
[TBL] [Abstract][Full Text] [Related]
23. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin.
Tay MY; Fraser JE; Chan WK; Moreland NJ; Rathore AP; Wang C; Vasudevan SG; Jans DA
Antiviral Res; 2013 Sep; 99(3):301-6. PubMed ID: 23769930
[TBL] [Abstract][Full Text] [Related]
24. Targeting dengue virus NS4B protein for drug discovery.
Xie X; Zou J; Wang QY; Shi PY
Antiviral Res; 2015 Jun; 118():39-45. PubMed ID: 25796970
[TBL] [Abstract][Full Text] [Related]
25. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
[TBL] [Abstract][Full Text] [Related]
26. Dengue virus vaccine development.
Yauch LE; Shresta S
Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
[TBL] [Abstract][Full Text] [Related]
27. Cell-based antiviral assays for screening and profiling inhibitors against dengue virus.
Gong EY; Clynhens M; Ivens T; Lory P; Simmen K; Kraus G
Methods Mol Biol; 2013; 1030():185-94. PubMed ID: 23821269
[TBL] [Abstract][Full Text] [Related]
28. Nordihydroguaiaretic acid (NDGA) inhibits replication and viral morphogenesis of dengue virus.
Soto-Acosta R; Bautista-Carbajal P; Syed GH; Siddiqui A; Del Angel RM
Antiviral Res; 2014 Sep; 109():132-40. PubMed ID: 25017471
[TBL] [Abstract][Full Text] [Related]
29. Important advances in the field of anti-dengue virus research.
Julander JG; Perry ST; Shresta S
Antivir Chem Chemother; 2011; 21(3):105-16. PubMed ID: 21233532
[TBL] [Abstract][Full Text] [Related]
30. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S; Pilankatta R; Khanna N; Swaminathan S
Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
[TBL] [Abstract][Full Text] [Related]
31. [Dengue fever: from disease to vaccination].
Teyssou R
Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
[TBL] [Abstract][Full Text] [Related]
32. Discovery of Dengue Virus NS4B Inhibitors.
Wang QY; Dong H; Zou B; Karuna R; Wan KF; Zou J; Susila A; Yip A; Shan C; Yeo KL; Xu H; Ding M; Chan WL; Gu F; Seah PG; Liu W; Lakshminarayana SB; Kang C; Lescar J; Blasco F; Smith PW; Shi PY
J Virol; 2015 Aug; 89(16):8233-44. PubMed ID: 26018165
[TBL] [Abstract][Full Text] [Related]
33. A novel flavivirus entry inhibitor, BP34610, discovered through high-throughput screening with dengue reporter viruses.
Yang CC; Hu HS; Lin HM; Wu PS; Wu RH; Tian JN; Wu SH; Tsou LK; Song JS; Chen HW; Chern JH; Chen CT; Yueh A
Antiviral Res; 2019 Dec; 172():104636. PubMed ID: 31654671
[TBL] [Abstract][Full Text] [Related]
34. DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus.
Costa SM; Freire MS; Alves AM
Vaccine; 2006 May; 24(21):4562-4. PubMed ID: 16140430
[TBL] [Abstract][Full Text] [Related]
35. Immunomodulating and antiviral activities of Uncaria tomentosa on human monocytes infected with Dengue Virus-2.
Reis SR; Valente LM; Sampaio AL; Siani AC; Gandini M; Azeredo EL; D'Avila LA; Mazzei JL; Henriques Md; Kubelka CF
Int Immunopharmacol; 2008 Mar; 8(3):468-76. PubMed ID: 18279801
[TBL] [Abstract][Full Text] [Related]
36. Strategies for the identification of inhibitors of West Nile virus and other flaviviruses.
Shi PY
Curr Opin Investig Drugs; 2002 Nov; 3(11):1567-73. PubMed ID: 12476954
[TBL] [Abstract][Full Text] [Related]
37. Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection.
Alen MM; Kaptein SJ; De Burghgraeve T; Balzarini J; Neyts J; Schols D
Virology; 2009 Apr; 387(1):67-75. PubMed ID: 19264337
[TBL] [Abstract][Full Text] [Related]
38. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses.
Lee E; Pavy M; Young N; Freeman C; Lobigs M
Antiviral Res; 2006 Jan; 69(1):31-8. PubMed ID: 16309754
[TBL] [Abstract][Full Text] [Related]
39. Testing antiviral compounds in a dengue mouse model.
Schul W; Yip A; Shi PY
Methods Mol Biol; 2013; 1030():269-81. PubMed ID: 23821275
[TBL] [Abstract][Full Text] [Related]
40. Peptides as Therapeutic Agents for Dengue Virus.
Chew MF; Poh KS; Poh CL
Int J Med Sci; 2017; 14(13):1342-1359. PubMed ID: 29200948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
